Research map: Real-world effectiveness, response patterns and clinical implementation of Mavacamten in obstructive hypertrophic cardiomyopathy: Insights from the SWISS-MAVA cohort

Back to the article

Papers in this map

  1. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial · Iacopo Olivotto · 2020 · 1285 citations · Cited by this paper
  2. Real-world mavacamten: What SWISS-MAVA adds · Roberto Licordari · 2026 · Cites this paper
  3. SGLT2 inhibitors and cardiovascular outcomes in patients with diabetes following hematopoietic stem cell transplantation: A propensity-matched cohort study · 2026 · Related
  4. Association of Obesity With Adverse Long-term Outcomes in Hypertrophic Cardiomyopathy · Carlo Fumagalli · 2019 · 164 citations · Cited by this paper
  5. Interpreting the athlete's ECG to prevent sudden death: An old tool in constant evolution · 2026 · Related
  6. Mavacamten: a first-in-class myosin inhibitor for obstructive hypertrophic cardiomyopathy · Eugene Braunwald · 2023 · 160 citations · Cited by this paper
  7. Clinical outcomes, frailty and biomarker profiles in cardiac amyloidosis-related worsening heart failure: an exploratory analysis · 2026 · Related
  8. Long-term effect of mavacamten in obstructive hypertrophic cardiomyopathy · Pablo García‐Pavía · 2024 · 106 citations · Cited by this paper
  9. Incidence and parameters associated with early diagnosis in unexplained syncope patients undergoing implantable loop recorder · 2026 · Related
  10. Dose-Blinded Myosin Inhibition in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy: Outcomes Through 32 Weeks · Milind Y. Desai · 2022 · 93 citations · Cited by this paper
  11. Unveiling the relationship between Fontan fenestration closure and hemodynamic profile:a single-center study · 2026 · Related
  12. Mavacamten: Real-World Experience From 22 Months of the Risk Evaluation and Mitigation Strategy (REMS) Program · Milind Y. Desai · 2024 · 40 citations · Cited by this paper
  13. Temporal changes in BNP levels and their prognostic impact on future cardiac events in patients undergoing transcatheter aortic valve implantation · 2026 · Related
  14. Real-world experience with mavacamten in obstructive hypertrophic cardiomyopathy: Observations from a tertiary care center · Milind Y. Desai · 2024 · 38 citations · Cited by this paper
  15. Left atrial adaptation to different overloads: is atrial enlargement always related to atrial dysfunction? · 2026 · Related
  16. Eighteen‐Month Real‐World Experience Using Mavacamten for Treatment of Obstructive Hypertrophic Cardiomyopathy in a Racially Diverse Population · Diego Ramonfaur · 2024 · 31 citations · Cited by this paper
  17. From prognostication to therapeutic guidance in cardiovascular-kidney-metabolic syndrome · 2026 · Related
  18. The European Medicines Agency assessment of mavacamten as treatment of symptomatic obstructive hypertrophic cardiomyopathy in adult patients · J. Hans DeVries · 2023 · 18 citations · Cited by this paper
  19. Characteristics and outcomes of patients with possible versus definite infective endocarditis: A nationwide cohort study from the NIDUS Database · 2026 · Related
  20. Stage-specific therapy for hypertrophic cardiomyopathy · Alessia Argirò · 2023 · 16 citations · Cited by this paper
  21. Long-term outcomes of ICE-guided left atrial appendage occlusion from a large single-center experience · 2026 · Related
  22. Efficacy of cardiac myosin inhibitors mavacamten and aficamten in hypertrophic cardiomyopathy: a systematic review and meta-analysis of randomised controlled trials · Ayesha Aman · 2025 · 16 citations · Cited by this paper
  23. Pharmacogenetic Influences Over Mavacamten Pharmacokinetics: Considerations for the Treatment of Individuals With Hypertrophic Cardiomyopathy · Kathryn A. McGurk · 2024 · 9 citations · Cited by this paper
  24. Characteristics and Outcomes of Mavacamten Use in 2440 Patients With Obstructive Hypertrophic Cardiomyopathy · Ingy Mahana · 2025 · 8 citations · Cited by this paper
  25. Untitled · Cited by this paper

Source: OpenAlex (CC0)